Drugs / Sym004
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02083679 | Jul 2014 → Aug 2015 | non-small cell lung carcinoma | EMD Serono | Terminated | No outcome recorded |
| Phase 1 | NCT01955473 | Oct 2013 → Oct 2015 | cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02924233 | Nov 2016 → Feb 2017 | non-small cell squamous lung carcinoma | Symphogen A/S | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02568046 | Mar 2016 → May 2017 | colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 1/2 | NCT01117428 | Mar 2010 → Feb 2015 | colorectal cancer | Symphogen A/S | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03549338 | Nov 2018 → Mar 2019 | carcinoma, colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 2 | NCT02965417 | Dec 2016 → Jan 2017 | colorectal cancer | Symphogen A/S | Withdrawn | No outcome recorded |
| Phase 2 | NCT02540161 | Feb 2016 → Jul 2019 | malignant glioma | Annick Desjardins | Completed | No outcome recorded |
| Phase 2 | NCT01417936 | Jul 2011 → Oct 2012 | head and neck squamous cell carcinoma | Symphogen A/S | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02083679 ↗ |
| Action | Inhibit | “In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands.” PMID 25962717 ↗ May 2015 |
| Modality | Monoclonal antibody | “Sym004, a novel 1:1 mixture of two chimeric monoclonal antibodies (992 and 1024)” PMID 25952795 ↗ May 2015 |
| Route | Intravenous | “Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion” NCT01417936 ↗ |
| Target | EGFR | “Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes.” PMID 25962717 ↗ May 2015 |